{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:59:32Z","timestamp":1784033972171,"version":"3.55.0"},"reference-count":26,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Taichung Veterans General Hospital","award":["TCVGH-1103301B"],"award-info":[{"award-number":["TCVGH-1103301B"]}]},{"name":"Taichung Veterans General Hospital","award":["TCVGH-1113301B"],"award-info":[{"award-number":["TCVGH-1113301B"]}]},{"name":"Taichung Veterans General Hospital","award":["TCVGH-1113301C"],"award-info":[{"award-number":["TCVGH-1113301C"]}]},{"name":"Taichung Veterans General Hospital","award":["VTA111-V1-2-3"],"award-info":[{"award-number":["VTA111-V1-2-3"]}]},{"name":"Taichung Veterans General Hospital","award":["TCVGH-110G742"],"award-info":[{"award-number":["TCVGH-110G742"]}]},{"name":"Taichung Veterans General Hospital","award":["VGHUST110-G7-4-2"],"award-info":[{"award-number":["VGHUST110-G7-4-2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: The benefits of hepatitis C virus (HCV)eradication for hepatocellular carcinoma (HCC) patients in Barcelona Clinic Liver Cancer (BCLC) stage B\/C remain uncertain. Methods: In this hospital-based cohort study, all HCV-infected patients with BCLC stage B\/C HCC during the period January 2017 to March 2021 were retrospectively screened, with 97 patients who had completed direct-acting antiviral (DAA) therapy being enrolled for final analysis. Results: In total, the sustained virological response (SVR) rate was 90.7%. In logistic regression analysis, progressive disease (PD) to prior tumor treatments was significantly associated with SVR failure (odds ratio 5.59, 95% CI 1.30\u201324.06, p = 0.021). Furthermore, the overall survival (OS) rate was significantly higher in the SVR group than that in the non-SVR group (1-year OS: 87.5% vs. 57.1%, p = 0.001). SVR was found to be an independent factor related to OS (hazard ratio 8.42, 95% CI 2.93\u201324.19, p = 0.001). However, even upon achieving SVR, the OS rates in BCLC stage C or Child\u2013Pugh stage B patients remained poor. Conclusions: In BCLC stage B\/C HCC, DAA could achieve a high SVR rate except in those patients with PD to prior HCC treatments. SVR was related to improvements in OS; therefore, DAA therapy should be encouraged for patients diagnosed without a short life expectancy.<\/jats:p>","DOI":"10.3390\/v14112316","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T11:53:55Z","timestamp":1666612435000},"page":"2316","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B\/C Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-2665","authenticated-orcid":false,"given":"Shou-Wu","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan"},{"name":"School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, Chung Hsing University, Taichung 40227, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Shu","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Shun","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan"},{"name":"School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"},{"name":"Ph.D. Program in Translational Medicine, Chung Hsing University, Taichung 40227, Taiwan"},{"name":"Institute of Biomedical Sciences, Chung Hsing University, Taichung 40227, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-5425","authenticated-orcid":false,"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-4315","authenticated-orcid":false,"given":"Teng-Yu","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan"},{"name":"School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.2003.030353","article-title":"Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C","volume":"53","author":"Yoshida","year":"2004","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1159\/000520721","article-title":"Advances in the era of direct-acting antivirals for hepatitis C in patients with unresectable hepatocellular carcinoma","volume":"40","author":"Chen","year":"2022","journal-title":"Dig. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of sustained virologic response with direct- acting antiviral treatment on mortality in patients with advanced liver disease","volume":"69","author":"Backus","year":"2019","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jvh.13579","article-title":"Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence","volume":"28","author":"Ohki","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2019.04.017","article-title":"Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis","volume":"71","author":"Ji","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lee, S.W., Yang, S.S., Lien, H.C., Peng, Y.C., Tung, C.F., and Lee, T.Y. (2022). The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164874"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jhep.2021.01.046","article-title":"Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)","volume":"74","author":"Reig","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e17692","DOI":"10.1097\/MD.0000000000017692","article-title":"Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status","volume":"98","author":"Lee","year":"2019","journal-title":"Medicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lai, C.Y., Yang, S.S., Lee, S.W., Tsai, H.J., and Lee, T.Y. (2021). Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation. J. Clin. Med., 10.","DOI":"10.3390\/jcm10214883"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.transproceed.2009.03.094","article-title":"Predictive factors of recurrence of hepatocellular carcinoma after liver transplantation: A multivariate analysis","volume":"41","author":"Lai","year":"2009","journal-title":"Transplant. Proc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/apt.13343","article-title":"Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies","volume":"42","author":"Deterding","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.cgh.2019.09.033","article-title":"Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection","volume":"18","author":"Tapper","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An Elita study based on the ELTR registry","volume":"69","author":"Belli","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11938-018-0178-y","article-title":"Interaction between hepatocellular carcinoma and hepatitis C eradication with direct-acting antiviral Therapy","volume":"16","author":"Konjeti","year":"2018","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.4254\/wjh.v7.i17.2080","article-title":"Immunology of hepatocellular carcinoma","volume":"7","author":"Sachdeva","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","article-title":"Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals","volume":"66","author":"Prenner","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jmii.2019.09.006","article-title":"Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan","volume":"54","author":"Chi","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2018.09.029","article-title":"Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy","volume":"70","author":"Minami","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.21873\/anticanres.14968","article-title":"Direct-acting Antiviral Therapy Improves the outcome of chronic hepatitis C\/intermediate-stage B hepatocellular carcinoma patients","volume":"41","author":"Shao","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_25","first-page":"7543","article-title":"Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study","volume":"25","author":"Tsai","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2316\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:00:58Z","timestamp":1760144458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,22]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["v14112316"],"URL":"https:\/\/doi.org\/10.3390\/v14112316","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,22]]}}}